| Revenue Growth | US Healthcare up 5% to $78.3B; International up 5% to $7.8B. |
|---|---|
| Mgmt Confidence | High confidence in long-term targets and new pharmaceutical-centric operating model. |
| Demand Visibility | Expect specialty distribution revenue to reach approximately $100 billion in FY2027. |
| Margin Trends | Adjusted gross margin expanded 57 basis points to 4.04% in Q4. |
| Op. Leverage | Operating expenses grew 23% primarily due to OneOncology acquisition impact. |
| Pricing Power | Manufacturer list price reductions created a $2.8 billion headwind to revenue. |
| Vol vs Price | Growth driven by specialty volume strength and GLP-1 demand ($2.8B increase). |
| Segment Growth | Specialty segment long-term operating income growth targeted at mid-teens percentage. |
| New Clients | Acquired OneOncology; majority interest agreement in American Oncology Network (AON). |
| Capex & Debt | FY2027 CAPEX $1B; $1.25B share repurchases; $1B debt repayment planned. |
| Regulatory | Monitoring IRA impacts and potential policy changes following the recent election. |
| Commentary | Strategic pivot to a pharmaceutical-centric model focusing on high-margin specialty services. |
| New Launches | Introduced AI-powered tools for independent pharmacies at ThoughtSpot trade show. |
Growth
FY2026 revenue grew 5% to $337B; adjusted diluted EPS rose 12% to $17.97.
Outlook
FY2027 EPS guided to $19.40-$19.75; specialty segment operating income growth expected at 18-21%.
Risks
Management used vague language regarding the specific financial impact of losing the Option Care contract.
The company's earnings call, NYSE: COR, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Cencora, Inc.: key numbers
- Share price
- $356.94Close, Nov 16
- Market cap
- $68.1B
- Shares outstanding
- 190.83MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cencora, Inc.
All →Cencora Business Update
Cencora, Inc. announced a reorganization of its operating model and reporting structure to advance growth priorities and improve visibility. Beginning in fiscal 2027, the company will report results across three segments: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The filing includes supplemental unaudited historical segment data for fiscal 2025 and 2026 recast under this new structure to assist investor analysis.
Cencora Financial Results
Cencora reported fiscal year 2026 revenue of $337.4 billion, up 5.0% year-over-year, and adjusted diluted EPS of $17.97. The company introduced a new operating model and reportable segments following its acquisition of OneOncology and provided fiscal 2027 adjusted EPS guidance of $19.40 to $19.75.
- Term
- FY2026
“Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results.”
Robert P. Mauch, President and Chief Executive Officer of Cencora
“As we enter fiscal 2027, our new operating model is designed to strengthen our execution and provide visibility to our progress.”
Robert P. Mauch, President and Chief Executive Officer of Cencora
Cencora SVP & CAO Lazarus Krikorian Sells $326K of Stock
Lazarus Krikorian, SVP & CAO, sold 986 shares of Cencora, Inc. at $330.96 a share, worth $326K in total on Nov 2, 2026. Shares held after the trade: 14,197 (-6.5%).
- Value
- $326K
- Shares
- 986
- Price
- $330.96
- Role
- SVP & CAO
- Holding change
- -6.5%
- Trade date
- Nov 2, 2026
Cencora Signs $2.4B M&A Deal with American Oncology Network, Inc.
Cencora has signed a definitive agreement to acquire American Oncology Network (AON) for an enterprise value of $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The acquisition expands Cencora's oncology management services organization (MSO) platform by adding a network of over 350 oncology providers across 21 states.
- Value
- $2.4B
- Counterparty
- American Oncology Network, Inc.
Cencora SVP & CAO Lazarus Krikorian Sells $299K of Stock
Lazarus Krikorian, SVP & CAO, sold 986 shares of Cencora, Inc. at $303.18 a share, worth $299K in total on Oct 1, 2026. Shares held after the trade: 15,183 (-6.1%).
- Value
- $299K
- Shares
- 986
- Price
- $303.18
- Role
- SVP & CAO
- Holding change
- -6.1%
- Trade date
- Oct 1, 2026
Cencora Leadership Change
Cencora, Inc. appointed Robert E. Sanchez, the former Executive Chair and CEO of Ryder System, Inc., to its Board of Directors effective October 1, 2026. In connection with the appointment, the Board increased its size from ten to eleven members. Mr. Sanchez will receive standard non-employee director compensation, including a pro-rated annual equity award.
- Counterparty
- Robert E. Sanchez